Bio-Techne launches HPV assay in Europe

By staff writers

July 6, 2022 -- Bio-Techne on Wednesday announced the European launch and CE-IVD marking of its RNAscope ISH Probe High Risk HPV assay to detect high-risk human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma patients.

RNAscope in situ hybridization (ISH) is a highly sensitive and specific spatial biology technology, Bio-Techne said.

The assay enables users to visualize and localize biomarker expression patterns by light microscopy. It is used in clinical laboratories with the CE-IVD marked Bond RNAscope Brown detection kit on the automated Leica Biosystems Bond-III stainer.

The assay detects high-risk HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82.

Bio-Techne to acquire Namocell
Bio-Techne has reached a deal to acquire Namocell, a Mountain View, CA-based single cell selection and sorting technology provider.
Bio-Techne, Nonangen enter into agreement for Oncuria
Bio-Techne and Nonagen Bioscience recently entered into an agreement for Bio-Techne's R&D Systems unit to exclusively manufacture Nonagen’s Oncuria bladder...
Bio-Techne touts study with ExoDx prostate test
Bio-Techne is touting a new clinical study that indicates that its exosome-based, noninvasive urine prostate test, ExoDx Prostate test (EPI), correlates...
Bio-Techne launches multiplex spatial genomics assay
Bio-Techne has expanded its RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed,...
Bio-Techne teams up with Leica to bring RNAscope to Europe
Global life sciences firm Bio-Techne and pathology workflow software developer Leica Biosystems have launched Bio-Techne's RNAscope in situ hybridization...

Copyright © 2022

Last Updated mp 7/6/2022 1:53:20 PM